

**Outcome of Transjugular Intrahepatic
Portosystemic Shunt (TIPS) in Budd-Chiari
Syndrome patients Single centre experience**

Thesis

Submitted for Partial Fulfillment of master Degree of
Tropical Medicine

By

Shimaa Zaghlol Mostafa Behary

M.B.B.Ch.

Ain Shams University

Under Supervision of

Professor / Mohammad Amin Sakr

Professor of Tropical Medicine

Faculty of Medicine-Ain Shams University

Doctor /Hany Mansour khalil Dabbous

Assistant Professor of Tropical Medicine

Faculty of Medicine-Ain Shams University

Doctor/ Mohammed El Ghareeb Abo El Maaty

Assistant Professor of Diagnostic Radiology and Nuclear
Medicine

Faculty of Medicine-Ain Shams University

Faculty of Medicine

Ain Shams University

2015



Acknowledgment

*First and foremost thanks to **ALLAH**, the most merciful.*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Mohammad Amin Sakr**, Professor of Tropical Medicine, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his supervision.*

*My deepest gratitude to **Dr. Hany Mansour Khalil Dabbous** Assistant Professor of Tropical Medicine, Ain Shams University for his sincere guidance and valuable suggestions in this study. He gave me much of his valuable time, experience and support that cannot be expressed in words.*

*No words can fulfill the feeling of thanks I carry to **Dr. Mohammed El Ghareeb Abo El Maaty**, assistant, Professor of Radiodiagnosis and Nuclear medicine, Ain Shams University, for his support and supervision.*

*Also, I must express my deepest thanks to all members of **Budd Chiari Study Group (BCSG)** and **Egyptian Association for Study of Vascular Liver Disorders (EASVLD)**, who helped me in this work and patients who allowed me to produce this study.*

Finally I am particularly and deeply thankful to my family, specially my parents, my husband and my children for their continuous prayers, without their encouragement, help, understanding and moral support, this work could not have been achieved.

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	v
List of Figures	viii
Introduction	1
Aim of the work	5
Review of Literature	
Budd-Chiari syndrome(BCS)	42
Transjugular Intrahepatic Portosystemic Shunt.....	47
Patients and Methods	77
Results.....	81
Discussion	105
Summary	116
Conclusions.....	119
Recommendations.....	120
References.....	121
Arabic Summary.....	—

List of Abbreviations

ALP	Alkaline phosphatase
APAs	Antiphospholipid antibodies
APC	Activated protein C
APLAS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time
AT III	Antithrombin III
BCS	Budd-Chiari syndrome
BCSG	Budd-Chiari Study Group
CT	Computed Tomography
DIC	Disseminated intravascular coagulation
DVT	Deep venous thrombosis
FVLM	Factor V Leiden mutation
HH	Hyperhomocysteinemia
HVOO	Hepatic venous outflow obstruction
HVPG	Hepatic venous pressure gradient
HVs	Hepatic veins
IVC	Inferior vena cava
JAK₂	Janus tyrosine kinase-2
LA	Lupus Anticoagulant
LAP	Leukocyte alkaline phosphatase
LHV	Left hepatic vein
LMWH	Low molecular weight heparin
MELD	Model for end-stage liver disease
MHV	Middle hepatic vein
MPDs	Myeloproliferative disorders

List of Abbreviations *(Cont.)*

MRI	Magnetic resonance imaging
MRV	Magnetic resonance venography
MSCT	Multislice CT
MTHFR	Methylenetetrahydro-folate reductase
OCPs	Oral Contraceptive Pills
P. ANCA	Peripheral anti neutrophilic cytoplasmic antibody
PC	Protein C
PGM	Prothrombin gene mutation
PHG	Portal hypertensive gastropathy
PI	Prognostic index
PM	Prothrombin mutation
PNH	Paroxysmal nocturnal hemoglobinuria
PPG	Portal pressure gradient
PS	Protein S
PTFE	Polytetrafluoroethylene
PV	Portal vein
PVT	Portal vein thrombosis
RHV	Right hepatic vein
rTPA	Recombinant tissue plasminogen activator
TIPS	Transjugular Intrahepatic Portosystemic Shunt
UNOS	United Network for Organ Sharing
US	Ultrasound

List of Tables (in Review Of literature)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Summary of Sonographic Findings in BCS	23
Table (2):	Proposed work-up for acquired conditions in primary BCS	27
Table (3):	Proposed work-up for inherited conditions in primary BCS	28
Table (4):	Warfarin properties:	32
Table (5):	Unfractionated heparin properties	33
Table (6):	Low molecular weight heparin (LMWH) properties.....	34
Table (7):	Indications of TIPS	48
Table (8):	The contraindication to placement of TIPS	48

List of Tables (in Results)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1a):	Age and gender distribution of study population (n=121).....	81
Table (1b):	Etiology of BCS in the studied patients (n=121	82
Table (2):	Classification of the studied cases according to the relevant scoring systems (MELD, Child-Pugh, Rotterdam and BCS-TIPS scores):	82
Table (3):	Immediate (first month) post procedure complications in the studied patients (n=121).....	84
Table (4):	Short term impact of TIPS on the clinical status in the studied patients (n=121)	85
Table (5):	Effect of TIPS on liver function tests (total=104)	86
Table (6):	The rate of stent occlusion during short term follow-up (less than 1 year, n=104).....	87
Table (7):	The frequency of stent occlusion during short term follow-up in the studied patients (less than 1 year, n=104)	88
Table (8):	Pattern of management of post TIPS occlusion during short term follow up	89
Table (9):	Impact of TIPS on Clinical status of patients(n =99).....	90
Table (10):	Impact of TIPS on liver profile during Long term follow up (n=99).....	91

List of Tables (in Results)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (11):	The rate of stent occlusion during long term follow up (total= 99)	92
Table (12):	The frequency of stent occlusion during long term follow up in the studied patients (n=99).....	95
Table (13):	Pattern of Management of post TIPS occlusion	96
Table (14):	Impact of TIPS on Child Pugh and MELD mean scores (n=99)	97
Table (15):	Calculation of 1, 3, 5 year Survival rate of the studied patients	98
Table (16):	Causes of mortality among the studied cases (total=121).....	99
Table (17):	Association between survival and other short and long term outcome parameters	100
Table (18):	Association between survival on one hand and age, Child Pugh and MELD score pre and post TIPS on the other hand.....	103
Table (19):	Association between survival on one hand and Rotterdam score and BCS- TIPS score on the other hand.	104

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Trend of performing TIPS over the study duration	83
Figure (2):	Immediate (first month) post procedure complications in the studied patients.....	84
Figure (3):	Short term impact of TIPS on the clinical status in the studied patients	85
Figure (4):	Short term effect of TIPS on liver function tests.....	86
Figure (5):	The rate of stent occlusion during short term follow-up	87
Figure (6):	The frequency of stent occlusion during short term follow-up in the studied patients	88
Figure (7):	Pattern of management of post TIPS occlusion during short term follow up.....	89
Figure (8):	Impact of TIPS on Clinical status of patients in long term follow-up.....	90
Figure (9):	Impact of TIPS on liver profile during Long term follow up	91
Figure (10):	The rate of stent occlusion during long term follow up.....	92

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (11):	Occluded stent.....	93
Figure (12):	Patent TIPS after recanalization by angiography.....	93
Figure (13):	Time till post TIPS occlusion	94
Figure (14):	The frequency of stent occlusion during long term follow up in the studied patients	95
Figure (15):	Pattern of Management of post TIPS occlusion	96
Figure (16):	Impact of TIPS on Child Pugh and MELD mean scores	97
Figure (17):	Kaplan-Meier Survival curve for all patients who underwent TIPS	98
Figure (18):	Causes of mortality among the studied cases	99
Figure (19):	Status of liver profile in short term and long term follow-up	101
Figure (20):	The rate of stent occlusion during short term and long term follow up	101
Figure (21):	The frequency of stent occlusion during short term and long term follow up	102
Figure (22):	Rotterdam score	104

Introduction

Budd-Chiari syndrome is a congestive hepatopathy caused by obstruction of the hepatic venous outflow at any level from the small hepatic veins to the junction of the inferior vena cava (IVC) with the right atrium (*Valla, 2009*).

George Budd described this hepatic disorder in 1845, and **Chiari** added the first pathologic description of a liver with “obliterating endophlebitis of the hepatic veins” in 1899 (*Chung et al., 2006*).

The hepatic outflow obstruction results in portal hypertension and sinusoidal congestion with ischaemic hepatocyte dysfunction.

This causes the dominant clinical features of abdominal pain, hepato- and splenomegaly, ascites, and oesophageal varices and the development of fulminant hepatic failure (*Valla, 2009*).

The most common underlying disorders in patients with BCS are myeloproliferative disorders such as polycythaemia vera and essential thrombocytosis. Some patients may have a combination of thrombophilias (*Ranjani et al., 2008*).

Other common associations include oral contraceptive use, protein C and S deficiencies, antiphospholipid syndrome, antithrombin III deficiency, paroxysmal nocturnal

haemoglobinuria, malignancy, Behcet's syndrome and trauma (*Denninger et al., 2000*).

The Budd–Chiari syndrome is termed primary or secondary based on the aetiology and site of venous outflow obstruction. Primary BCS originates from within the lumen of the veins or venules and results from thrombosis, webs or endophlebitis. Secondary BCS results from an extra-luminal lesion such as tumour, abscess or cyst, which can invade the lumen or cause extrinsic compression of the hepatic venous outflow tract (*Hoekstra and Janssen, 2008*).

Four main clinical variations have been described: fulminant, acute, subacute or chronic (*Darwish et al., 2009*).

The subacute form is the most common presentation and is characterized by slow accumulation of ascites. Hepatocellular damage is minimal due to the development of hepatic and portal venous collaterals.

The fulminant form is rare and is defined as the development of hepatic encephalopathy within 8 weeks of the onset of jaundice.

Acute BCS has a rapid onset, intractable ascites and a short duration of symptoms. Collateral venous channels do not develop in the acute form of BCS. Chronic BCS usually occurs in the background of cirrhosis.

Early diagnosis is fundamental, Doppler-ultrasound, computed tomography or magnetic resonance imaging of hepatic veins and inferior vena cava are usually successful in demonstrating non-invasively the obstacle or its consequences, the collaterals to hepatic veins or inferior vena cava

Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the severity of liver disease and it can be medical, surgical, or interventional. A therapeutic strategy has been proposed where anticoagulation, correction of risk factors, diuretics and prophylaxis for portal hypertension are used first; then angioplasty for short-length venous stenosis or TIPS for long segment occlusion, and ultimately liver transplantation (*Valla, 2009*).

Interventional radiology options as angioplasty and transjugular intrahepatic portosystemic shunt (TIPS) should be considered. This may reverse the hepatic congestion and halt the progression of the disease (*Li et al., 2009*).

TIPS decompress the liver by creating an alternative venous outflow tract (*Panagiotou et al., 2007*). It is particularly useful, either alone or as a bridge to liver transplantation, in patients with an acute presentation such as those with variceal bleeding, and patients with fulminant

hepatic failure or chronic illness in whom thrombolysis and angioplasty were unsuccessful (*Khuroo et al., 2005*).

TIPS may be preferred over surgical shunting because it avoids laparotomy and has less periprocedure mortality and morbidity (*Corso et al., 2008*). Although long-term patency rate is only about 49%, patients in whom stent stenosis occurs do not generally worsen, perhaps because the shunt allows time for collateral circulation to develop (*Perello et al., 2002*).

The recently introduced, polytetrafluoroethylene-covered stents may improve the patency rates and have been shown to reduce the incidence of TIPS dysfunction in BCS patients (*Cura et al., 2008 and Murad et al., 2008*). Other important complications of TIPS procedure is the occurrence of thrombosis, infection and portosystemic encephalopathy (*Eldorrry et al., 2011*).

Aim of the work

The aim of this study is to:

- 1- Determine the short term outcome of TIPS in Budd-Chiari syndrome patients in the form of immediate post procedure complications and possible effect of procedure on presenting symptoms.
- 2- Determine Long term outcome of TIPS in the form of stent patency and patient survival.